David Venables presented to a full room of investors at yesterday’s ARM Cell & Gene Therapy Investor Day in New York.
A new video from Synpromics’ investor, Calculus Capital, discusses why they invest and how this has aided development of our synthetic promoter technology.
Sarah Haecker Meeks and David Venables enjoyed the sun in San Diego earlier this month for the annual ARM Cell & Gene Meeting on the Mesa.
Scotland is home to a flourishing life science industry with government supported plans to increase its size to £8bn by 2025.
In May, Synpromics attended the ASGCT annual general meeting in Chicago.